Skip to main content
Top

27-01-2025 | Systemic Lupus Erythematosus | REVIEW ARTICLE

Risk and protective factors of disease flare during pregnancy in systemic lupus erythematosus: a systematic review and meta-analysis

Authors: Yudi Yang, Yangzhong Zhou, Xueyang Zhang, Can Huang, Lingshan Liu, Jiuliang Zhao, Xinping Tian, Mengtao Li, Xiaofeng Zeng, Yan Zhao, Yijun Song

Published in: Clinical Rheumatology

Login to get access

Abstract

To synthesize available evidence on predictive factors associated with systemic lupus erythematosus (SLE) flares during pregnancy, we systematically searched MEDLINE, Embase, and the Cochrane Library through January 2024 for observational studies on risk and protective factors of SLE flares during pregnancy. Odds ratios (OR) and mean differences (MD), as well as their 95% confidence intervals (CI) were used to quantify effect sizes. We employed fixed-effect or random-effect models based on heterogeneity assessments (I2 statistics). Sensitivity analyses were performed using the leave-one-out method, and publication bias was assessed through Egger’s test. Thirty-two studies were included in the meta-analysis. Significant baseline SLE characteristics associated with higher risks for flares during pregnancy were identified: thrombocytopenia (with OR [95%CI], 2.29 [1.14–4.58]), hypocomplementemia (1.70 [1.28–2.27]), anti-dsDNA positivity (1.43 [1.16–1.77]), and a history of lupus nephritis (2.34 [1.70–3.21]). Protective factors included achieving remission before pregnancy (0.32 [0.20–0.49]) and antimalarial use at baseline (0.71 [0.55–0.92]) and during pregnancy (0.44 [0.33–0.58]). Additional risk factors included baseline glucocorticoid usage (1.51 [1.17–1.94]), glucocorticoid administration during pregnancy (3.39 [1.90–6.06]), use of other immunosuppressive drugs at baseline (1.46 [1.00–2.12]), and hypertension (2.16 [1.45–3.23]). Furthermore, individuals in the flare group were younger, had higher baseline disease activity, and lower C3/C4 levels compared to the non-flare group. This study highlighted the critical role of managing SLE disease activity prior to pregnancy to minimize flare risks, and identified significant risk and protective factors associated with flares. These evidences facilitate better clinical management strategies for pregnant women with SLE.
Key Points
Synthesizes existing evidence on the risk and protective factors associated with SLE flares during pregnancy.
Highlights the critical importance of effectively managing disease activity prior to conception.
Provides insights to enhance risk stratification and management strategies for pregnancies in patients with SLE.
Appendix
Available only for authorised users
Literature
9.
go back to reference Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76:476–485. https://doi.org/10.1136/annrheumdis-2016-209770CrossRefPubMed Andreoli L, Bertsias GK, Agmon-Levin N, Brown S, Cervera R, Costedoat-Chalumeau N et al (2017) EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 76:476–485. https://​doi.​org/​10.​1136/​annrheumdis-2016-209770CrossRefPubMed
28.
go back to reference Wu J, Di W (2018) Pregnancy outcome in Chinese women with systemic lupus erythematosus: a retrospective study of 255 cases in a single center. Int J Clin Exp Med 11:966–974 Wu J, Di W (2018) Pregnancy outcome in Chinese women with systemic lupus erythematosus: a retrospective study of 255 cases in a single center. Int J Clin Exp Med 11:966–974
36.
go back to reference Fatemi A, Fard RM, Sayedbonakdar Z, Farajzadegan Z, Saber M (2013) The role of lupus nephritis in development of adverse maternal and fetal outcomes during pregnancy. Int J Prev Med 4:1004–1010PubMedPubMedCentral Fatemi A, Fard RM, Sayedbonakdar Z, Farajzadegan Z, Saber M (2013) The role of lupus nephritis in development of adverse maternal and fetal outcomes during pregnancy. Int J Prev Med 4:1004–1010PubMedPubMedCentral
49.
go back to reference Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD et al (2020) American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72:529–556. https://doi.org/10.1002/art.41191 Sammaritano LR, Bermas BL, Chakravarty EE, Chambers C, Clowse MEB, Lockshin MD et al (2020) American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases. Arthritis Rheumatol 72:529–556. https://​doi.​org/​10.​1002/​art.​41191
51.
go back to reference Langham J, Barut V, Samnaliev M, Langham S, Weir S, Wang X, et al (2021) Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 5:rkab061. https://doi.org/10.1093/rap/rkab061 Langham J, Barut V, Samnaliev M, Langham S, Weir S, Wang X, et al (2021) Disease severity, flares and treatment patterns in adults with systemic lupus erythematosus in the UK: a real-world observational retrospective cohort analysis. Rheumatol Adv Pract 5:rkab061. https://​doi.​org/​10.​1093/​rap/​rkab061
52.
go back to reference de Luca Montes RA, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R et al (2024) Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study. Adv Rheumatol (London, England) 64:38. https://doi.org/10.1186/s42358-024-00366-yCrossRef de Luca Montes RA, Huq M, Godfrey T, Oon S, Calderone A, Kandane-Rathnayake R et al (2024) Association of systemic lupus erythematosus standard of care immunosuppressants with glucocorticoid use and disease outcomes: a multicentre cohort study. Adv Rheumatol (London, England) 64:38. https://​doi.​org/​10.​1186/​s42358-024-00366-yCrossRef
Metadata
Title
Risk and protective factors of disease flare during pregnancy in systemic lupus erythematosus: a systematic review and meta-analysis
Authors
Yudi Yang
Yangzhong Zhou
Xueyang Zhang
Can Huang
Lingshan Liu
Jiuliang Zhao
Xinping Tian
Mengtao Li
Xiaofeng Zeng
Yan Zhao
Yijun Song
Publication date
27-01-2025
Publisher
Springer International Publishing
Published in
Clinical Rheumatology
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-025-07341-y

Keynote series | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more